https://www.selleckchem.com/products/jzl184.html
group than in the control group at 7 (96.30% vs. 39.13%, P0.0001) and 10 days (96.30% vs. 56.52%, P=0.0008). No allergic reactions or anaphylactic responses were reported in this trial. RDN markedly inhibited SARS-CoV-2 proliferation and viral plaque formation in vitro. In addition, RDN significantly reduced inflammatory cytokine production in infected cells. RDN relieves clinical symptoms in patients with COVID-19 and reduces SARS-CoV-2 infection by regulating inflammatory cytokine-related disorders, suggestion that this medication
Like
Comment
Share
